IGC Pharma Inc.

About IGC Pharma Inc.

IGC Pharma is a pharmaceutical company focused on developing innovative treatments for neurological disorders, particularly Alzheimer's disease. Their mission is to impact lives by creating drugs that address unmet needs in dementia and agitation, with a commitment to patients, caregivers, and families.

Products & Services

IGC-AD1:A drug in Phase 2b trials targeting agitation in dementia due to Alzheimer's disease, showing promising results.

TGR-63:A drug candidate in development, specifics not detailed in content but part of the pipeline for Alzheimer's treatment.

IGC-M3:A compound demonstrating in vitro efficacy against Alzheimer's by targeting key drivers of disease progression.

MINT-AD:A proprietary AI platform designed to predict Alzheimer's risk and accelerate early detection.

Artificial Intelligence Platforms:Advanced AI tools for Alzheimer's research and treatment, to be presented at AAIC 2025.

Specialties

Alzheimer's Disease Treatment Neurological Disorders Artificial Intelligence in Healthcare Drug Development for Dementia and Agitation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 234000 MR: - FA: approximately $234,000 FAN: 234000	D: 2026-01-05 FD: 2026-01-05	1 investors
2	RT: Private Placement T: - FT: Private Placement	A: 475000 MR: - FA: approximately $475 thousand FAN: 475000	D: 2025-04-24 FD: 2025-04-24	3 investors
3	RT: Private Placement T: - FT: Private Placement	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2024-03-22 FD: 2024-03-22	1 investors
4	RT: Revolving Line of Credit T: - FT: Revolving Line of Credit	A: 12000000 MR: - FA: $12 million FAN: 12000000	D: 2023-07-07 FD: 2023-07-07	2 investors
5	RT: Private Placement of Common Stock T: - FT: Private Placement of Common Stock	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2023-07-06 FD: 2023-07-06	2 investors

Registered Direct Offering Latest

2026-01-05

$234K

1 investor (Pro only)

Private Placement 2025-04-24

$475K

Private Placement 2024-03-22

$3.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard Prins

Chairman

LinkedIn (Pro only)

J

Jim Moran

Former U.S. Representative

T

Terry Lierman

Member of the Board of Visitors, La Follette School of Public Affairs

T

Terry McAuliffe

Governor of Virginia

H

Howard Gutman

Former Ambassador to Belgium

R

Ram Mukunda

Biomedical Engineer CEO, Director

View 42 more team members with Pro

Unlock Full Team Directory

Recent News

IGC Pharma Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised